The following <u>Listing of the Claims</u> will replace all prior versions and all prior listings of the claims in the present application:

- 1-11 (canceled)
- 12. (currently amended) A method of treating <u>a</u> cancerous disease sensitive to a compound of general formula (I)

wherein R₁ and R₂ are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents[[.]],

comprising administering a pharmaceutical preparation comprising a pharmaceutically effective amount of at least one of said compounds compound of formula (I) to a human being or a mammal in need thereof in an amount effective to treat said cancerous disease.

- 13. (previously presented) The method of claim 12, wherein said cancerous disease is parvocellular bronchial carcinoma or colorectal carcinoma.
- 14. (canceled)
- 15. (currently amended) The method according to claim 12, wherein said cancerous disease is selected from testicular tumors tumor, ovarian earcinomas carcinoma, bladder earcinomas carcinoma, colonic earcinomas carcinoma, prostatic earcinomas carcinoma, parvocellular and non-parvocellular bronchial earcinomas carcinoma, earcinomas carcinoma of the cephalic and cervical parts, earcinomas carcinoma of the thoracic and

- abdominal regions, cervical and endometrial earcinomas carcinoma, sarcomas sarcoma, melanomas melanoma and leukemias leukemia.
- 16. (currently amended) The method of claim 12, wherein in the compound of formula (I) R_1 and R_2 are each independently a straight-chain C_{1-14} alkyl residue or a C_{3-14} cycloalkyl residue-each.
- 17. (previously presented) The method of claim 12, wherein in the compound of formula (I) R₁ and R₂ are each CH₃CH₂.
- 18. (previously presented) The method of claim 12, wherein the compound of formula (I) is dimethylxanthogenate platinum (II) complex or diethylxanthogenate platinum (II) complex.
- 19. (previously presented) The method of claim 12, wherein said compound further comprises a pharmaceutically compatible inert carrier or a diluent.